Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study Evaluating the Systemic and Mucosal Safety and Immunogenicity of a Recombinant HIV-1 Gp 160 (MN/LAI) Administered by Transmucosal (Nasal or Vaginal) Routes, Alone or Formulated With DC-Chol, in HIV Negative Volunteers (ANRS VAC14)

NCT00122564 is registered in ClinicalTrials.gov with French National Agency for Research on AIDS and Viral Hepatitis as lead sponsor.

NCT NCT00122564
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00122564 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study Evaluating the Systemic and Mucosal Safety and Immunogenicity of a Recombinant HIV-1 Gp 160 (MN/LAI) Administered by Transmucosal (Nasal or Vaginal) Routes, Alone or Formulated With DC-Chol, in HIV Negative Volunteers (ANRS VAC14)
Lead sponsor
French National Agency for Research on AIDS and Viral Hepatitis
Phase
Phase 1
Overall status
Terminated
Start date
June 30, 2003
Completion date
April 30, 2005
Enrollment
36
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections